Abstract: Methods for treating and reducing risk of cerebral amyloid angiopathy (CAA) using nasal vaccination with a proteosome adjuvant.

Abstract: A novel method for erbB-2 kinase inhibition by compounds identifies through computational modeling and data processing and/or rational and de novo drug design is provided the compounds bind erbB-2 kinase molecules and which can be used as erbB-2 kinase agonists or antagonists. These compounds are useful especially in the treatment of cancer, particularly breast cancer, and can be used alone or in combination with other chemotherapeutic agents, particularly with hercetin, a humanized anti-HER-2 antibody, or with radiation therapy. A specific compound which is exemplified is “compound B17”=methyl-(p-nitrophenyl)-2-propynoate.

Abstract: The invention relates to a method for producing a radioactive brachytherapy source material comprising indium-114m in radioactive equilibrium with indium-114 as main radioactive isotopes. A new radioactive brachytherapy source material comprises indium-114m in radioactive equilibrium with indium-114 as main radioactive isotopes. A new encapsulated radioactive brachytherapy source comprises the new radioactive brachytherapy source material.

Abstract: The present invention is concerned with controlled release compositions for oral administration comprising galantamine; and with processes of preparing such controlled release compositions.

Abstract: The preparation of novel microemulsions to be used as precursors for solid nanoparticles is described. The microemulsion precursors consist of either alcohol-in-fluorocarbon microemulsions, liquid hydrocarbon-in-fluorocarbon microemulsions, or liquid hydrocarbon-in-water microemulsions. The formed solid nanoparticles have diameters below 200 nanometers and can be made to entrap various materials including drugs, magnets, and sensors. The solid nanoparticles can be made to target different cells in the body by the inclusion of a cell-specific targeting ligand. Methods of preparing the novel microemulsion precursors and methods to cure solid nanoparticles are provided.

Abstract: Preparation of particles of an active substance having a layer of an additive at the particle surfaces, by dissolving both the active substance and the additive in a vehicle to form a target solution, and contacting the target solution with an anti-solvent fluid using a SEDS™ particle formation process, to cause the active substance and additive to coprecipitate. The additive is typically a protective additive, in particular a taste and/or odour masking agent. Also provided is a particulate coformulation made by the method, which has a finite gradient in the relative additive concentration, which concentration increases radially outwards from the active-rich core to the additive-rich surface of the particles.

Abstract: Method for obtaining BOLD MRI images with allosteric effector compounds are disclosed. Methods for the determination of tumor oxygenation and for an optimal time for initiating radiation therapy are also disclosed.

Abstract: The present invention relates generally to a method of improving the antioxidant status of an infant. More particularly, the present invention relates to a method of improving the antioxidant status of an infant by administering a mixture of natural tocopherols. The natural tocopherol mixture is an effective blend of ?- and ?-tocopherol. For ease of administration and improved taste, the mixture of natural tocopherols are typically delivered in vehicle which may be in the form, for example, of a tablet, capsule, liquid, and nutritional formula. The present invention also relates to a method of improving the antioxidant status of an infant by supplementing the lactating woman wherein the supplemented breast milk is fed to the infant. Additionally, the present invention relates to a method of improving the antioxidant status of a newborn infant by supplementing the pregnant woman.

Abstract: Compositions and methods for delivering active agents to the skin of a subject, including a polymer, an active ingredient and a solvent are disclosed, the compositions being capable of delivery by rolling, spreading, aerosol or in droplets and of forming a film in contact with the skin.

Abstract: Nanometer particles of poorly water-soluble or substantially water-insoluble compound are produced by finely-spraying a non-aqueous solution of said compound into a heated and fluidized bed of carrier excipient. The resulting product consists of a free flowing mixture of relatively large particles of carrier excipient and nanometer sized particles (less than 3 ?m)) of compound.

Abstract: A method for the preparation of compositions, preferably pharmaceutical compositions, in form of expanded, mechanically stable, lamellar, porous, sponge-like or foam structures out of solutions and dispersions results in a favored pharmaceutical product. This method comprises the steps of a) preparing a solution or a homogeneous dispersion of a liquid and a compound selected from the group consisting of one or more pharmaceutically active compounds, one or more pharmaceutically suitable excipients, and mixtures thereof, followed by b) the expansion of the solution or the homogeneous dispersion without boiling.

Abstract: A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having, by differential scanning calorimetry, no observable endotherm and an exotherm at between 273.6 and 275.6° C., and a solution NMR spectrum with multiplets at 1.7 and 3.7 ppm shifts.

Abstract: Compositions and methods for administering a therapeutic agent to a mammal are disclosed. The compositions comprise either (i) vesicles comprising an amphiphilic substituted fullerene, wherein the therapeutic agent is present in the vesicle interior or between layers of the vesicle wall, (ii) a substituted fullerene, comprising a fullerene core and a functional moiety, wherein the therapeutic agent is associated with the substituted fullerene, or (iii) carbon nanotubes, wherein the therapeutic agent is covalently bonded to the carbon nanotubes.

Abstract: The present invention concerns a food composition having a foodstuff and substantially pure eritadenine. The invention also concerns a food additive having a liquid or solid material intended to be added to a foodstuff, said material being supplemented with substantially pure eritadenine. Furthermore, the invention concerns methods for preparation of the food composition so as to provide a food composition having an increased level of eritadenine in comparison to the inherent eritadenine level of the foodstuff(s) included in the food composition.

Abstract: A method for producing a drug system which is a reversible gelled matrix with entrapped drug. The gel is made by combining a polysaccharide, such as dextran, a polymer of glucose, with a natural macromolecule, such as the lectin, concanavalin A, with binding sites for monomers of the polysaccharide. The drug is released in response to exposure of the matrix to free carbohydrate containing the monomer of the polysaccharide for which the natural macromolecule binds.

Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.

Abstract: The present invention is concerned with biomedical device comprising (a) a biocompatible organic or inorganic bulk material and (b) a coating comprising polymerizable carbon-carbon double bonds covalently attached to at least part of the bulk surface. The biomedical devices of the invention are radiation sensitive and may be used, for example, as ready-to-use corneal onlay in ophthalmic surgery.

Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Abstract: This invention relates to a convenient and safe product and method of applying glycopyrrolate topically in order to reduce excessive sweating in localized areas for those who suffer from this condition. This invention also relates to combining oral and topical delivery of glycopyrrolate to reduce excessive sweating and minimize side effects. This invention also relates to a convenient and safe product and method of applying glycopyrrolate topically to areas of compensatory sweating after endoscopic thoracic sympathectomy.

Abstract: This invention provides extended release potassium chloride granules consisting essentially of potassium chloride crystals having a mesh size of about 20–60 mesh that are coated only with ethylcellulose. The granules may be compressed into tablets that disintegrate rapidly in an aqueous environment to provide uniform dissolution of the potassium chloride. Tablets containing about 10 to about 20 milliequivalents potassium may be formulated in accordance with the invention. Processes to produce extended release granules without using surfactants, processing aids or other coating aids are also provided by this invention. A method is further provided whereby a patient's supplemental potassium requirements are met by administering an appropriate combination of dosage units chosen from available dosage units containing different quantities of potassium.